- Sagami Rubber Industries Co., Ltd.
- Issuing Office:
Department of Health and Human Services
|Public Health Service|
|Food and Drug Administration|
10903 New Hampshire Avenue
Silver Spring, MD 20993
MAY 04, 2016
Director, Healthcare Products Division
Sagami Rubber Industries Co. , Ltd.
2-1 , Moto-Cho, Atsugi-Shi
Dear Mr. Tadenuma:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter (WL #481765, dated November 24, 2015). Based on our evaluation, it appears that you have
addressed the violation contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Carl Fischer, Ph.D.
Division of International Compliance Operations
Office of Compliance
Center for Devices and Radiological Health
David P. Mayer
710 West Napa Street, Suite 4
Sonoma, California 95476